Odile Leroy: Perspectives and challenges of malaria vaccine. Why we must do more.Abstract: Bull. Acad. Natle Méd, 2007, 30 October, 191, no7, 1249-1260.

Nielsen MA, Resende M, Alifrangis M, turner L, Hviid L, Theander T, Salanti A. Plasmodium falciparum: VAR2 CSA expressed during pregnancy-associated malaria in partially resistant to proteolytic cleavage by trypsin. Experimental Parasitology. 2007; 117: 1-8 (VAR2 CSA)

Benoit G, Smith JD, Viebig NK, Gysin J, Scherf A. Pregnancy-associated malaria: Parasite binding natural immunity and vaccine development. International Journal for Parasitology. 2007; 273-83 (Var2-CSA DBL3-X)

Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, BoladA, Berzins K, Corradin G, Leroy OTheisen M, Sauerwein RW. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.Vaccine. 2007 Apr 12;25(15):2930-40 (GLURP-LSP)

Sirima SB, Nébié I, Ouédraogo A, Tiono AB, Konaté AT, Gansané A, Dermé AI, Diarra A, Ouédraogo A, Soulama I, Cuzzin-Ouattara N, Cousens S, Leroy O.  Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine. 2007 Mar 30;25(14):2723-32 (MSP3-LSP)